- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: Keratoacanthoma.
Displaying page 1 of 1.
EudraCT Number: 2006-001528-38 | Sponsor Protocol Number: PROSKIN 01 | Start Date*: 2007-01-12 |
Sponsor Name:Charité Universitätsmedizin Berlin | ||
Full Title: Prevention of skin cancer in high risk patients after conversion a to Sirolimus-based immunosuppressive | ||
Medical condition: Medical condition: renal transplant-patients at high-risk for skin cancer Transplant recipients have a high risk to develop skin malignancies. This depends on the immunosuppressive drugs and is rel... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-005481-35 | Sponsor Protocol Number: 2012-005481-35 | Start Date*: 2013-09-02 | |||||||||||
Sponsor Name:Uppsala University Hospital | |||||||||||||
Full Title: A controlled, randomized, assessor blinded, open-label study to investigate whether initiation of everolimus will reduce the incidence of developing a new Squamous Cell Carcinoma (SCC) and other ma... | |||||||||||||
Medical condition: Squamous cell carcinoma (SCC) and other malignancies in renal transplanted recipients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004577-12 | Sponsor Protocol Number: BRF116613 | Start Date*: 2015-03-23 | |||||||||||
Sponsor Name:GlaxoSmithKline, S.A. | |||||||||||||
Full Title: Phase II biomarker study evaluating the upfront combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib versus the combination after eight weeks of monotherapy with dabrafenib or tra... | |||||||||||||
Medical condition: patients with metastatic and unresectable stage III or IV melanoma harbouring an activating BRAF mutation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006041-36 | Sponsor Protocol Number: PH-L19IL2TNFBASK-04/21 | Start Date*: 2022-02-08 |
Sponsor Name:Philogen S.p.A. | ||
Full Title: A phase II study of L19IL2/L19TNF in patients with skin cancers amenable to intralesional treatment | ||
Medical condition: Patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention, including: • Basal cell carcinoma (BCC) • Cutaneous squamou... | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
